Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results

Transcode Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
10/02/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/02/2023 4 Dudley Robert Michael (CEO) has filed a Form 4 on Transcode Therapeutics, Inc.
Txns: Bought 98,000 shares @ $0.51, valued at $50k
09/28/2023 8-K Quarterly results
09/27/2023 424B4 Form 424B4 - Prospectus [Rule 424(b)(4)]:
08/24/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "TransCode Therapeutics Announces First Subject Dosed with Radiolabeled TTX-MC138 in First-In-Human Clinical Trial August 23, 2023 Designed to demonstrate delivery of TTX-MC138 to metastatic lesions"
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/04/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
07/28/2023 8-K Quarterly results
06/16/2023 SC 13D/A Dudley Robert Michael reports a 6% stake in TransCode Therapeutics, Inc.
06/08/2023 8-K Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; T...
Docs: "SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of June 6, 2023, between TransCode Therapeutics, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act , the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purcha...",
"TransCode Therapeutics Announces Pricing of $7 Million Public Offering BOSTON, June 6, 2023 -- TransCode Therapeutics, Inc. , an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the pricing of its public offering of an aggregate of 2,000,000 shares of its common stock , together with accompanying common stock warrants, at a public offering price of $3.50 per share and accompanying warrants. Each share of common stock is being offered in the offering together with a Series A-1 warrant to purchase one share of common stock at an exercise price of $3.25 per share and a Series A-2 warrant to purchase one share of common stock at an exercise price of $3.25 per share. The Series A-1 warrants will be exercisable immediately and will expire..."
06/07/2023 424B4 Form 424B4 - Prospectus [Rule 424(b)(4)]:
06/07/2023 EFFECT Form EFFECT - Notice of Effectiveness:
06/05/2023 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
05/19/2023 4 Manting Erik (Director) has filed a Form 4 on Transcode Therapeutics, Inc.
Txns: Granted 45,000 options to buy @ $0.2834, valued at $12.8k
05/19/2023 4 Marquet Magda (Director) has filed a Form 4 on Transcode Therapeutics, Inc.
Txns: Granted 45,000 options to buy @ $0.2834, valued at $12.8k
05/19/2023 4 Fitzgerald Thomas A (CFO) has filed a Form 4 on Transcode Therapeutics, Inc.
Txns: Granted 300,000 options to buy @ $0.2834, valued at $85k
05/19/2023 4 Dudley Robert Michael (CEO) has filed a Form 4 on Transcode Therapeutics, Inc.
Txns: Granted 735,000 options to buy @ $0.2834, valued at $208.3k
05/19/2023 4 Calais Philippe (Director) has filed a Form 4 on Transcode Therapeutics, Inc.
Txns: Granted 45,000 options to buy @ $0.2834, valued at $12.8k
05/19/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/19/2023 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
05/18/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
05/10/2023 4 Manting Erik (Director) has filed a Form 4 on Transcode Therapeutics, Inc.
Txns: Granted 9,500 options to buy @ $0.2985, valued at $2.8k
05/10/2023 4 Marquet Magda (Director) has filed a Form 4 on Transcode Therapeutics, Inc.
Txns: Granted 9,500 options to buy @ $0.2985, valued at $2.8k
05/10/2023 4 Calais Philippe (Director) has filed a Form 4 on Transcode Therapeutics, Inc.
Txns: Granted 9,500 options to buy @ $0.2985, valued at $2.8k
05/10/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
04/14/2023 8-K Quarterly results
04/14/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/31/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/31/2023 8-K Shareholder Nominations Pursuant to Exchange Act Rule 14a-11  Interactive Data
03/31/2023 10-K Annual Report for the period ended December 31, 2022
03/31/2023 8-K Quarterly results
Docs: "TransCode Therapeutics Reports 2022 Results; Provides Business Update"
02/10/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/01/2023 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy